SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):361P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Eslamy, H.
Right arrow Articles by Quon, A.
PubMed
Right arrow Articles by Eslamy, H.
Right arrow Articles by Quon, A.

Oncology-Clinical Diagnosis: Solid Tumors

Clinical Diagnosis-Solid Tumors Posters

F18-FDG PET/CT in assessing response of lung tumors to CyberKnife treatment

Hedieh Eslamy1, Jarrett Rosenberg1 and Andrew Quon1

1 Radiology, Stanford Hospital, Stanford, California

1528

Objectives: To determine the utility of F18-FDG PET/CT in assessing response to treatment in patients with medically inoperable T1-2N0 non-small cell lung cancer or solitary lung metastases undergoing hypo-fractionated CyberKnife treatment.

Methods: 12 patients underwent PET/CT scanning before and after CyberKnife treatment. All PET/CT scans were retrospectively reanalyzed. Using SUVmax as a guideline, each patient was classified as: Complete Metabolic Response (CMR), Partial Metabolic Response (PMR), Stable Metabolic Disease (SMD), Progressive Metabolic Disease (PMD) and Equivocal Metabolic Response (EMR). The imaging findings were correlated with local control and overall patient outcome.

Results: The pre- and post-treatment PET/CTs were performed 4 -78 days (median 41, SD ± 25) prior to and 80-201 days (median 111, SD ± 41) after treatment respectively. The length of follow-up after treatment ranged from 3.3 months to 2.3 years (median 7 months, SD ± 9 months). There were 4 cases each of CMR and PMR, and 2 each of SMD and EMR. All 4 with CMR had no evidence of disease (NED) on follow-up. Of the 4 with PMR, 2 had NED, one developed distant metastases (DM) and the 4th developed possible regional lymph node metastases. Of the 2 with SMD, one developed DM and the other had NED. Both cases with EMR developed DM. Post-treatment SUVmax was negatively correlated with metabolic response (Spearman rank-order correlation -0.934, p<.0001). Both EMR cases had SUVmax levels within the range of PMR cases. However, there was no relationship between clinical outcome and post-treatment SUVmax or change in SUVmax (Spearman rank-order correlation 0.307 and -0.402, p<.33 and <.28 respectively).

Conclusions: Using SUVmax as a guide, PET/CT can accurately assess metabolic response to Cyberknife treatment, but is insufficient to predict clinical outcome.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Eslamy, H.
Right arrow Articles by Quon, A.
PubMed
Right arrow Articles by Eslamy, H.
Right arrow Articles by Quon, A.